ABO-101 redePHine human data
ABO-101 uses LNP-delivered Cas12i2 editing to disrupt hepatic HAO1 in primary hyperoxaluria type 1. The Phase 1/2 redePHine study is identified as NCT06839235.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Disclosure is separate from demonstrating clinical benefit; any positive-endpoint version needs its own prespecified statistical threshold.
- Research candidate, not a live market, clinical probability, company equity or access to private shares.
Primary evidence
Phase 1/2 readout — date unconfirmed
Company context
Company-authored LinkedIn About explicitly states Type: Privately Held and links arbor.bio. Opened and checked October 31, 2026. This is an undated company self-report, not independent registry proof. The opened 2026 Metagenomi annual report also calls Arbor private.
Potential outcome market
Will Arbor publicly report treated-patient safety and urinary-oxalate data from redePHine by the market deadline?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.